Executive leadership at OSR Holdings.
Board of directors at OSR Holdings.
Research analysts covering OSR Holdings.
Recent press releases and 8-K filings for OSRH.
OSR Holdings Completes Woori IO Acquisition and Reviews Medical Device Subsidiary Combination
OSRH
M&A
New Projects/Investments
- OSR Holdings, Inc. (OSRH) officially closed its acquisition of Woori IO on January 26, 2026, making Woori IO a consolidated subsidiary.
- Historical shareholders of Woori IO have committed to a three-year equity alignment, agreeing to exchange their interests into OSRH common stock at a reference price of $10.00 per share.
- OSRH is conducting a strategic review for a potential combination of its medical device subsidiaries, Woori IO and RMC, with the aim of forming an integrated medical technology and distribution company that could potentially support a standalone IPO in Korea.
- The acquisition of Woori IO was completed through the issuance of equity interests of OSRK, an OSRH subsidiary, and no shares of OSRH's common stock were issued in the transaction.
6 hours ago
OSR Holdings' Woori IO Accelerates Commercial Launch Following FDA Clarification
OSRH
Product Launch
New Projects/Investments
M&A
- Woori IO, an OSR Holdings company, is accelerating its commercialization of noninvasive glucose monitoring wearables due to a recent FDA clarification.
- The FDA's guidance indicates that non-medical, wellness-oriented wearables generally fall outside medical device pre-market review, allowing Woori IO to expedite market entry with consumer-grade products.
- Woori IO will pursue a two-phase commercialization strategy, initially launching consumer wellness wearables and subsequently developing medical-grade Continuous Glucose Monitoring (CGM) solutions.
- This accelerated roadmap supports OSR Holdings' broader digital health strategy, with the share exchange transaction expected to complete on January 26, 2026.
5 days ago
OSR Holdings' Subsidiary Vaximm Receives Binding Term Sheet for VXM01 Global License
OSRH
New Projects/Investments
M&A
- OSR Holdings, Inc. announced that its subsidiary, Vaximm AG, received a binding term sheet from BCM Europe AG, the largest shareholder of OSR Holdings, for a global exclusive license of VXM01, Vaximm’s lead immunotherapy candidate.
- The agreement includes an upfront payment of $30 million, comprising $15 million in cash and $15 million in digital assets, along with up to $815 million in aggregate clinical, regulatory, and commercial milestone payments.
- The parties aim to finalize a definitive agreement by the end of May 2026, contingent on customary conditions, including an independent third-party fairness opinion given the related-party nature of the transaction.
Jan 14, 2026, 2:27 PM
OSR Holdings' Vaximm Subsidiary Receives Binding Term Sheet for VXM01 Licensing
OSRH
New Projects/Investments
- OSR Holdings' Swiss biotechnology subsidiary, Vaximm AG, has received a binding term sheet from BCM Europe AG for a global exclusive licensing transaction for its lead immunotherapy candidate, VXM01.
- The proposed agreement includes an upfront payment of $30 million, structured as 50% cash and 50% digital assets, and potential aggregate milestone payments of up to $815 million.
- A definitive agreement is targeted for execution by the end of May 2026, subject to Vaximm's board review, an independent fairness opinion, and other customary conditions.
Jan 12, 2026, 1:05 PM
OSR Holdings Completes Acquisition of Woori IO, Advancing Glucose Monitoring Technology
OSRH
M&A
New Projects/Investments
Product Launch
- OSR Holdings, Inc. announced that Woori IO Co., Ltd. shareholders approved a share exchange, making Woori IO a wholly-owned subsidiary of OSRK, OSR Holdings' Korean intermediate holding company.
- Woori IO, a developer of noninvasive glucose monitoring technology, is collaborating with Samsung Electronics on a Proof-of-Concept study in South Korea for regulatory approval.
- The company also plans to initiate U.S. market development and a U.S. FDA clinical trial for its technology through a collaboration with a research university.
Dec 19, 2025, 4:50 PM
OSR Holdings' Vaximm AG Updates Term Sheet for VXM01 Licensing Agreement
OSRH
New Projects/Investments
- OSR Holdings' subsidiary, Vaximm AG, and BCM Europe AG (BCME) have shortened the exclusivity period for their non-binding term sheet from six months to three months, with the expectation to finalize a definitive global licensing agreement for VXM01 by February 2026.
- The financial terms for the potential licensing agreement remain unchanged, including a $20 million upfront payment to Vaximm and up to $815 million in clinical, regulatory, and commercial milestone payments.
- This accelerated timeline reflects confidence in BCME's ability to efficiently mobilize capital and advance due diligence to position VXM01 for a major pharmaceutical partnership.
Dec 2, 2025, 2:53 PM
OSR Holdings' Subsidiary Vaximm AG Enters Term Sheet for VXM01 License
OSRH
New Projects/Investments
- OSR Holdings, Inc.'s subsidiary, Vaximm AG, entered into a non-binding term sheet with BCM Europe AG for a potential exclusive global licensing agreement for its VXM01 oral cancer immunotherapy platform.
- The agreement, dated November 21, 2025, includes a contemplated $20 million upfront payment and up to $815 million in clinical, regulatory, and commercial milestone payments to Vaximm.
- BCM Europe AG will act as a strategic financial intermediary, funding development and partnering activities to secure a global out-license with a major pharmaceutical company.
- The term sheet grants BCM Europe AG an exclusive 120-day period to finalize the definitive agreement.
Nov 25, 2025, 3:56 PM
OSR Holdings' Vaximm AG Enters Term Sheet for VXM01 License
OSRH
New Projects/Investments
- Vaximm AG, a subsidiary of OSR Holdings, has entered a non-binding term sheet with BCM Europe AG for a potential exclusive global licensing agreement for VXM01, its oral cancer immunotherapy platform.
- The proposed agreement includes a $20 million upfront payment and up to $815 million in clinical, regulatory, and commercial milestone payments to Vaximm.
- BCM Europe AG, OSRH's largest shareholder, would fund the partnering and development activities for VXM01 during a six-month exclusivity period.
- Vaximm will retain full ownership of its VXM01 intellectual property.
Nov 21, 2025, 2:20 PM
OSR Holdings Appoints Dr. Andreas Niethammer as CEO of Vaximm AG
OSRH
Management Change
New Projects/Investments
- OSR Holdings, Inc. announced the appointment of Dr. Andreas Niethammer as Chief Executive Officer (CEO) of its subsidiary, Vaximm AG, effective December 1, 2025.
- Dr. Niethammer, Vaximm's scientific co-founder and Chief Medical Officer, will lead the integration of Vaximm's immune activation platform with viral oncolysis technologies through a forthcoming strategic collaboration.
- This collaboration aims to build a next-generation immuno-oncology platform targeting renal cell carcinoma (RCC) and other advanced solid tumors.
Nov 14, 2025, 4:10 PM
OSR Holdings, Inc. to Acquire Woori IO, a Non-Invasive Glucose Monitoring Company
OSRH
M&A
New Projects/Investments
- OSR Holdings, Inc. (OSRH) has signed a definitive agreement to acquire Woori IO Co., Ltd. (WORIO), a South Korea-based medical-device company specializing in non-invasive glucose monitoring (NIGM) technology, for approximately KRW15bn (~$10.5 million).
- The acquisition is structured such that WORIO will become a wholly owned subsidiary of OSRH's Korean affiliate, OSR Holdings Co., Ltd. (OSRK), with former WORIO shareholders receiving OSRK shares.
- A key condition allows former WORIO shareholders to exchange their OSRK shares for 1,093,020 newly issued OSRH common shares at a ratio of 12.96 OSRH shares for each OSRK share, if OSRH's NASDAQ share price reaches $10.00 within three years of the share exchange.
- This strategic move aims to strengthen OSRH's medical-device platform and diversify its healthcare portfolio, tapping into the global glucose-monitoring market projected to exceed $40 billion by 2030. The transaction is expected to be effective on January 12, 2026, pending WORIO shareholder approval by December 19, 2025.
Oct 16, 2025, 3:10 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more